China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 27.24
-0.17 (-0.62%)
Aug 22, 2025, 2:45 PM CST
SHE:300294 Revenue
China Resources Boya Bio-pharmaceutical Group Co.,Ltd had revenue of 471.90M CNY in the quarter ending June 30, 2025, with 5.50% growth. This brings the company's revenue in the last twelve months to 1.85B, down -7.97% year-over-year. In the year 2024, China Resources Boya Bio-pharmaceutical Group Co.,Ltd had annual revenue of 1.73B, down -34.58%.
Revenue (ttm)
1.85B
Revenue Growth
-7.97%
P/S Ratio
7.43
Revenue / Employee
953.01K
Employees
1,938
Market Cap
13.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.73B | -917.08M | -34.58% |
| Dec 31, 2023 | 2.65B | -106.72M | -3.87% |
| Dec 31, 2022 | 2.76B | 108.17M | 4.08% |
| Dec 31, 2021 | 2.65B | 137.49M | 5.47% |
| Dec 31, 2020 | 2.51B | -395.73M | -13.60% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 41.90B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |